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Answers to questions
Question 1: How are the diabetes and renal disease con-
nected to each other, if at all? In principle, when a patient
has multiple signs, symptoms or laboratory abnormalities
they can be explained in one of four ways:
1) All the problems may be features of a single disease.
2) Some of the problems may be complications or side
effects of treatment given for one or more problems
or diseases.
3) One or more problems may be a complication of anoth-
er condition.
4) The patient may have multiple, unrelated diseases.
The first choice in formulating a differential diagnosis is
usually to find a single condition to explain everything. In a
patient with diabetes and proteinuria, the initial thought is
often diabetic nephropathy. However, diabetic patients are
more likely to have conditions other than diabetic nephrop-
athy [1]. This is particularly true in patients with short du-
ration of diabetes and good metabolic control. Our patient
has diabetes which is somewhat atypical for type 1 diabetes
with negative auto-antibodies and an unusually long
Bhoneymoon period^ with very low glycated haemoglobin
(HbA1C) levels [2]. The renal biopsy showed focal segmen-
tal glomerulosclerosis (FSGS), and she has other clinical
features, including short stature, poor effort tolerance and
abdominal pain. One needs to consider genetic causes of
diabetes that may account for some or all of these features.
The patient had received large doses of analgesics, but the
renal disease is unusual for analgesic nephropathy which
typically presents with papillary necrosis and reduced glo-
merular filtration rate (GFR). The association with drugs
other than phenacetin remains speculative [3]. Finally, the
patient could have two or more unrelated conditions.
Question 2: What further investigations should be under-
taken? It would be appropriate to undertake genetic testing
for diabetes and possibly for genetic causes of nephrotic
syndrome.
Question 3:What is the diagnosis?Genetic testing revealed
a mutation in mitochondrial DNA, m.3243A>G, which is
the most common cause of maternally inherited diabetes
and deafness (MIDD), a mitochondrial disorder character-
ized by maternally transmitted diabetes and sensorineural
deafness. She was also found to be heterozygous for a
missence variant of NPHS1, c.2746G>T; p.(Ala916Ser).
The patient therefore has MIDD, and the renal disease
may be aggravated by the NPHS1 variant.
This article refers to the article that can be found at http://dx.doi.org/
10.1007/s00467-016-3558-3.
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Maternally inherited diabetes and deafness was first described
in 1992 [4]. It is caused in the great majority of cases by an
adenine to guanine substitution at position 3243 of themitochon-
drial DNA (m.3243A>G) encoding the gene for leucine transfer
RNA. MIDD is frequently misdiagnosed as type 1 or type 2
diabetes, depending on the age of the patient and mode of pre-
sentation. About 1% of cases of diabetes are thought to be caused
by mutations in mitochondrial DNA, and the m.3243A>G mu-
tation accounts for about 85% of these [5].
The key clinical features are diabetes and deafness and their
presence in maternal relatives. As the case of our patient dem-
onstrates, these are not always present. The diabetes usually
presents insidiously, but in 20%of cases it presents acutely, with
ketoacidosis present in 8% of the latter cases [6]. About 75% of
diabetic patients with the m.3243A>G mutation have deafness,
which is sensorineural and due to cochlear disease [7].
Renal disease is common in patients with MIDD, especial-
ly females. In one series of 74 patients with MIDD, proteinuria
was greater in these patients than in control diabetic patients, and
chronic kidney disease (CKD) stage 3 or greater was four-to
sixfold higher despite lower HbA1C, lower blood pressure and a
3.7-fold lower incidence of diabetic retinopathy than controls [8].
The commonest histological pattern in patients undergoing renal
biopsy is FSGS, but tubulointerstitial disease and renal cysts have
also been described. The combination of nephropathy and deaf-
ness may lead to a mistaken diagnosis of Alport syndrome [9].
Several other features present in this patient are also ex-
plained by the m.3243A>G mutation, including short stature,
which is common and caused by a deficiency of growth hor-
mone–releasing hormone [10, 11]. Gastro-intestinal complaints
are also common, especially constipation and pseudo-
obstruction [5]. The inability to play competitive football is
likely to reflect impaired energy utilization and skeletal myop-
athy. Cardiomyopathy, retinal macular dystrophy and stroke,
features not present in our patient, are also described.
Our patient had early onset of several features. This is likely
to reflect high levels of heteroplasmy for the mutant mitochon-
drial DNA. The severity and early onset of renal disease may
also be due to the presence of a heterozygous mutation in
NPHS1. This gene codes for nephrin, an important component
of the glomerular slit diaphragm, and homozygous mutations
cause Finnish type congenital nephrotic syndrome.
A diagnosis of MIDD has several important implications for
treatment. Metformin should not be used for treating the diabe-
tes because of the increased risk of lactic acidosis. Antibiotics
such as tetracyclines and chloramphenicol which interfere with
mitochondrial function should also be avoided. Coenzyme Q10
has been shown to be beneficial in preventing hearing loss and
delaying progression of diabetes [12]. In patients who progress
to end stage renal failure, great caution should be exercised in
using maternal relatives as kidney donors.
Learning points
& Islet cell and glutamic acid decarboxylase (GAD) antibod-
ies should be tested in diabetic patients with atypical dis-
ease behaviour or features. Genetic testing should be con-
sidered in patients who test negative for islet cell and GAD
antibodies. A probability calculator for monogenic diabetes
is available at http://www.diabetesgenes.org/content/mody-
probability-calculator .
& Young diabetic patients with nephropathy and good diabet-
ic control are more likely to have disease other than diabetic
nephropathy, especially if there is no diabetic retinopathy.
& MIDDmay cause renal failure and deafness which may be
misdiagnosed as Alport syndrome.
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